# Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
Canonical URL: https://biopharmsignal.com/news/NRIX/nurix-therapeutics-outlines-2026-goals-and-objectives-for-advancing-bexobrutideg-and-its-pipeline-of-novel-degrader-based-medicines-in-cancer-and-autoimmune-diseases
Ticker: NRIX
Company: Nurix Therapeutics
Source: Nurix Therapeutics
Published: 2026-01-12 12:00 EST
Original Source URL: https://ir.nurixtx.com
## Summary

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Expand bexobrutideg into autoimmune and inflammatory indications,

## Article Body
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Expand bexobrutideg into autoimmune and inflammatory indications,
## Recent Company News
- 2026-05-14 20:06 EST — [Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-dermatology-annual-meeting) — Source: Nurix Therapeutics
- 2026-05-13 11:00 EST — [Nurix Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Nurix Therapeutics
- 2026-05-12 20:05 EST — [Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-bexobrutideg-oral-presentation-at-the-2026-european-hematology-association-congress) — Source: Nurix Therapeutics
- 2026-04-22 11:00 EST — [Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-new-preclinical-data-highlighting-breadth-of-targeted-protein-degradation-pipeline-at-aacr-2026) — Source: Nurix Therapeutics
- 2026-04-08 10:00 EST — [Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update) — Source: Nurix Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)